Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs TECH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TECH Captures Overall Composite Edge (55.4 HOLD vs 40.3 SELL), While MRNA Leads 4–2 on Growth & Valuation Pillars

TECH Overall Winner 6-Pillar Tally: MRNA 4 – 2 TECH Matrix Metrics: MRNA 4 – 6 TECH

As of Nov 20, 2026, Bio-Techne Corp. (TECH) captures the overall head-to-head institutional edge over Moderna, Inc. (MRNA) on higher Unified Composite conviction (55.4/100 HOLD vs. 40.3/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while MRNA wins 4–2 across the 6-pillar growth and valuation breakdown. MRNA trades at $195.00 (23.0x Forward P/E, -80.8% operating margin) versus TECH at $72.67 (42.8x Forward P/E, 21.7% operating margin).

  • Growth vs. Quality Trade-Off: TECH earns the overall head-to-head edge with a stronger Unified Composite Score (55.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.33β · 2% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile TECH is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs TECH
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
TECH NASDAQ Head-to-Head Winner
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.67
-0.04% 1D
Market Cap $11.4B
TTM Revenue $1.23B
Forward P/E 42.8x
Beta / 30D Vol 0.33β · 2% Vol
Unified Composite Score
55.4 / 100 HOLD
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.2%) with fading momentum, RSI 50
RSI-14: 49.7 · SMA20: $72.72 · SMA50: $72.58

6-Pillar Scorecard Institutional Category Breakdown (MRNA 4 – 2 TECH)

Columns: Metric · MRNA · TECH
1. Valuation Multiples MRNA
Forward P/E 23.0x 42.8x
Trailing P/E 23.0x 66.7x
PEG Ratio N/M 2.17x
EV / Revenue 33.1x 9.3x
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% +4.6%
Earnings Growth (YoY) -85.1% -25.0%
TTM Revenue (USD) $2.52B $1.23B
Market Cap $80.7B $11.4B
3. Profitability & Quality TECH
Gross Margin -42.0% 66.2%
Operating Margin -80.8% 21.7%
Net Profit Margin -110.5% 14.0%
Return on Equity (ROE) -34.5% 8.3%
4. Balance Sheet & Cash Flow TECH
Cash Generation (TTM) -$2.04B $325M EBITDA
Cash Flow Margin -81.0% 26.5% EBITDA Mgn
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $13.79 Book/Sh · 8.3% ROE
Dividend Yield None (0.00%) 0.33%
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 89.6% (52nd %ile) 40.9% (6th %ile)
Put/Call OI Skew 1.05x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 44.5% of Rev ($547M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (4) vs TECH (6)
Institutional Metric MRNA TECH Criterion Row Edge
Market Capitalization
Scale
$80.7B $11.4B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 66.7x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 42.8x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +4.6% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 21.7% Higher Margin TECH
Net Profit Margin
Profitability
-110.5% 14.0% Higher Margin TECH
Return on Equity (ROE)
Capital Efficiency
-34.5% 8.3% Higher ROE TECH
52-Week Range Position
Momentum
67% ($22–$281) 99% ($43–$73) Stronger Trend TECH
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.33β · 2% Vol Lower Realized Risk TECH
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 55.4 / 100 (HOLD) Higher Composite TECH
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $1.23B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 66.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 2.17x PEG · 9.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $325M EBITDA ($13.79 Book/Sh · 8.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TECH +3.84 pp
MRNA: -3.77% · TECH: +0.07%
3M Horizon MRNA +40.01 pp
MRNA: +40.4% · TECH: +0.39%
6M Horizon MRNA +265.22 pp
MRNA: +315.96% · TECH: +50.74%
1Y Horizon MRNA +680.75 pp
MRNA: +706.45% · TECH: +25.7%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs TECH. Trailing 12-month operating profitability (MRNA -80.8% vs TECH 21.7%) and valuation multiples (MRNA 23.0x vs TECH 42.8x Forward P/E) are benchmarked directly in Pillar 4 below.

MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x
TECH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin66.2%
Op. Margin21.7%
ROE / Fwd P/E8.3% · 42.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TECH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.9%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TECH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
TECH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.4B market capitalization and 21.7% operating margin.
OpEx & R&D Reinvestment 44.5% of Rev ($547M)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs TECH Key Questions & Quantitative Answers

As of Nov 20, 2026, Bio-Techne Corp. (TECH) captures the overall head-to-head institutional edge over Moderna, Inc. (MRNA) on higher Unified Composite conviction (55.4/100 HOLD vs. 40.3/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while MRNA wins 4–2 across the 6-pillar growth and valuation breakdown. MRNA trades at $195.00 (23.0x Forward P/E, -80.8% operating margin) versus TECH at $72.67 (42.8x Forward P/E, 21.7% operating margin). Growth vs. Quality Trade-Off: TECH earns the overall head-to-head edge with a stronger Unified Composite Score (55.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.33β · 2% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile TECH is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with TECH at +4.6% YoY revenue growth and -25.0% YoY earnings growth on $1.23B TTM revenue (66.2% gross margin, 21.7% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $1.23B for TECH. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 44.5% of Rev ($547M) (0 disclosures) for TECH.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas TECH trades at 42.8x Forward P/E, 66.7x Trailing P/E, 2.17x PEG, and 9.3x EV/Revenue (26.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus TECH (8.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, TECH carries 40.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.